Post Profile






Abemaciclib initial therapy improves outcome in endocrine-sensitive advanced breast cancer

(European Society for Medical Oncology) The results of the MONARCH 3 trial, presented at the ESMO 2017 Congress in Madrid (1), showed that adding the cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib to endocrine therapy improved progression-free survival compared to endocrine therapy alone in the total study population. While most women had substantial benefit from the addition of abemaciclib as initial treatment, around one-third of women may not need a CDK 4/6 inhibitor as initial treatment.
read more

share

Related Posts


Ribociclib improves progression-free survival in Asian women with advanced breast cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Ribociclib significantly improves progression-free survival in Asian women with advanced breast cancer, according to a sub-analysis of the MONALEESA-2 trial presented at the ESMO Asia 2016 Con...

Biothera To Present Research Results At European Society For Medical Oncology World Gastrointestinal Congress

Health : Medical News Today

Biothera has been accepted to present data from its Phase II clinical trial in stage IV KRAS-mutant colorectal cancer at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer June 22-25 in B...

Study in early stage breast cancer shows that even small tumors can be aggressive

Health : EurekAlert: Health

(European Society for Medical Oncology) Even small tumours can be aggressive, according to a study in patients with early stage breast cancer that will be presented at the ESMO 2017 Congress in Madrid. Researchers found that nearly ...

Mature results favor pembrolizumab as second-line treatment for bladder cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Mature results from the KEYNOTE-045 trial to be presented today at the ESMO 2017 Congress in Madrid have confirmed significantly longer survival in patients with advanced urothelial cancer who...

Almost 20 percent of breast cancer patients fail to complete prescribed endocrine therapy

Health : EurekAlert: Health

(European Society for Medical Oncology) Around 20 percent of breast cancer patients do not complete prescribed endocrine therapy, researchers report at the ESMO Asia 2016 Congress in Singapore. The study in over 5,500 women found th...

Comments


Copyright © 2016 Regator, LLC